Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer.

BACKGROUND & AIMS Kruppel-like factor 6 (KLF6) is a ubiquitous zinc finger tumor suppressor that is often mutated in prostate cancer. Our aims were to establish the frequency of KLF6 inactivation in sporadic and inflammatory bowel disease (IBD)-associated colorectal cancers (CRC); to correlate these abnormalities with mutation and/or loss of TP53, APC, and K-RAS; and to characterize the behavior of mutant KLF6 in colon-derived cell lines. METHODS We analyzed DNA isolated from 50 microdissected CRC cases, including 35 sporadic and 15 IBD-associated tumors. Microsatellite analysis and direct sequencing were used to establish the incidence of microsatellite instability, KLF6 and TP53 allelic imbalance, and KLF6, K-RAS, TP53, and APC mutation. Loss of growth suppressive function of the CRC-derived KLF6 mutants was characterized by in vitro thymidine incorporation assays and Western blotting. RESULTS KLF6 was inactivated by loss and/or mutation in most sporadic and IBD-related CRCs. The KLF6 locus was deleted in at least 55% of tumors, and mutations were identified in 44%. Rates of KLF6 loss and mutation were similar to those of TP53 and K-RAS in the same samples. KLF6 mutations were present in tumors with either microsatellite or chromosomal instability and were more common, particularly in the IBD-related cancers, in the presence of wild-type APC. Unlike wild-type KLF6, cancer-derived KLF6 mutants neither suppressed growth nor induced p21 following transfection into cultured cells. CONCLUSIONS Deregulation of KLF6 by a combination of allelic imbalance and mutation may play a role in the development of CRC.

[1]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Tsuneyoshi,et al.  Malignant Fibrous Histiocytoma , 1980, Virchows Archiv A.

[3]  P. Quirke,et al.  Heterogeneity of colorectal adenocarcinomas evaluated by flow cytometry and histopathology. , 1985, British Journal of Cancer.

[4]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[5]  Y. Nakamura,et al.  Allelotype of colorectal carcinomas. , 1989, Science.

[6]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[7]  S Ichii,et al.  Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. , 1992, Human molecular genetics.

[8]  Bert Vogelstein,et al.  APC mutations occur early during colorectal tumorigenesis , 1992, Nature.

[9]  P. Rabinovitch,et al.  Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. , 1992, Gastroenterology.

[10]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[11]  R. Beart,et al.  Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. , 1995, Cancer research.

[12]  J. Benhattar,et al.  Molecular genetics of dysplasia in ulcerative colitis. , 1995, European journal of cancer.

[13]  J. Zenklusen,et al.  Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. , 1995, Oncogene.

[14]  I. Talbot,et al.  Colorectal cancer in idiopathic inflammatory bowel disease. , 1996, Seminars in diagnostic pathology.

[15]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[16]  B. Strauss.  Silent and multiple mutations in p53 and the question of the hypermutability of tumors. , 1997, Carcinogenesis.

[17]  F. Bosman,et al.  Genetic diversity at the p53 locus between primary human colorectal adenocarcinomas and their lymph‐node metastases , 1997, International journal of cancer.

[18]  P. Peltomäki.  DNA mismatch repair gene mutations in human cancer. , 1997, Environmental health perspectives.

[19]  L. Roncucci,et al.  K‐ras and p53 mutations in hereditary non‐polyposis colorectal cancers , 1997, International journal of cancer.

[20]  S. Friedman,et al.  Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Hsieh,et al.  Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. , 1998, Cancer research.

[22]  R. Lidereau,et al.  Genetic aspects of prostate cancer , 1998, Virchows Archiv.

[23]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[24]  A. Millar,et al.  Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. , 1999, Cancer research.

[25]  T. Sugai,et al.  Analysis of subclonal expansion of colorectal carcinomas by flow cytometry , 1999, Virchows Archiv.

[26]  F. Pontén,et al.  A high frequency of sequence alterations is due to formalin fixation of archival specimens. , 1999, The American journal of pathology.

[27]  D. Louis,et al.  Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer. , 1999, Gastroenterology.

[28]  A. Vecchione,et al.  Intratumoral heterogeneity in colorectal carcinoma: trucut sampling for DNA ploidy analysis. , 1999, Anticancer research.

[29]  D J Lockhart,et al.  Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. , 2000, Genome research.

[30]  J. Martignetti,et al.  Malignant fibrous histiocytoma: Inherited and sporadic forms have loss of heterozygosity at chromosome bands 9p21–22—evidence for a common genetic defect , 2000, Genes, chromosomes & cancer.

[31]  J. Herman,et al.  Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. , 2000, Cancer research.

[32]  R. Lewontin,et al.  Mutation and cancer , 2000 .

[33]  T D Jenkins,et al.  The Krüppel‐like transcriptional factors Zf9 and GKLF coactivate the human keratin 4 promoter and physically interact , 2000, FEBS letters.

[34]  R. Houlston,et al.  What we could do now: molecular pathology of colorectal cancer , 2001, Molecular pathology : MP.

[35]  K. Chew,et al.  Altered Distribution of β-Catenin, and Its Binding Proteins E-Cadherin and APC, in Ulcerative Colitis–Related Colorectal Cancers , 2001, Modern Pathology.

[36]  S. Friedman,et al.  KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer , 2001, Science.

[37]  M. Nilbert,et al.  Beta-catenin activation through mutation is rare in rectal cancer. , 2001, Cancer genetics and cytogenetics.

[38]  Benjamin Geiger,et al.  Down-Regulation of β-Catenin by Activated p53 , 2001, Molecular and Cellular Biology.

[39]  F T Bosman,et al.  Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma , 2001, International journal of cancer.

[40]  B. Dastugue,et al.  Co-localization of KLF6 and KLF4 with pregnancy-specific glycoproteins during human placenta development , 2001, Mechanisms of Development.

[41]  C. Cordon-Cardo,et al.  Genetic alterations in tp53 in recurrent urothelial cancer: a longitudinal study. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  Michael A. Choti,et al.  A Phosphatase Associated with Metastasis of Colorectal Cancer , 2001, Science.

[43]  N. Wong,et al.  Colorectal neoplasia in ulcerative colitis—recent advances , 2001, Histopathology.

[44]  S. Friedman,et al.  Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. , 2002, Blood.

[45]  Y. Zeng,et al.  [Mutation analysis of KLF6 gene in human nasopharyngeal carcinomas]. , 2002, Ai zheng = Aizheng = Chinese journal of cancer.

[46]  F. Sato,et al.  Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. , 2002, Cancer cell.

[47]  S. Knuutila,et al.  Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array , 2002, Oncogene.

[48]  S. Markowitz,et al.  Genetic and epigenetic alterations in colon cancer. , 2002, Annual review of genomics and human genetics.

[49]  S. Y. Park,et al.  Development and applications of a beta-catenin oligonucleotide microarray: beta-catenin mutations are dominantly found in the proximal colon cancers with microsatellite instability. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  H. Frierson,et al.  Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. , 2003, The American journal of pathology.

[51]  M. Hollstein,et al.  Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes , 2003, British Journal of Cancer.

[52]  Y. Jeng,et al.  KLF6, a putative tumor suppressor gene, is mutated in astrocytic gliomas , 2003, International journal of cancer.